Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Ocuphire Pharma Inc

CUSIP: 67577R952 | 3 institutional holders

Quarters

Q3 2026 Q4 2025 Q2 2025 Q1 2025 Q4 2024

Compare Detailed Historical Funds Options Short Interest 13D/13G Peers Targeting Trading Summary Profile